Charles Schwab Trust Co Acquires Shares of 3,101 Biogen Inc. $BIIB

Posted by on Aug 11th, 2026

Charles Schwab Trust Co bought a new position in Biogen Inc. (NASDAQ:BIIB – Free Report) during the 2nd quarter, HoldingsChannel reports. The fund bought 3,101 shares of the biotechnology company’s stock, valued at approximately $670,000.

A number of other institutional investors have also recently made changes to their positions in BIIB. Rothschild Investment LLC increased its position in shares of Biogen by 12.3% during the fourth quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock valued at $90,000 after acquiring an additional 56 shares in the last quarter. Meeder Advisory Services Inc. lifted its position in Biogen by 1.2% in the 1st quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company’s stock valued at $866,000 after acquiring an additional 57 shares in the last quarter. Kera Capital Partners Inc. boosted its stake in Biogen by 3.5% during the 1st quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company’s stock valued at $316,000 after purchasing an additional 58 shares during the last quarter. Parallel Advisors LLC increased its holdings in shares of Biogen by 1.5% in the 1st quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock worth $801,000 after purchasing an additional 65 shares in the last quarter. Finally, Itau Unibanco Holding S.A. increased its holdings in shares of Biogen by 24.4% in the 4th quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 66 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Price Performance

NASDAQ BIIB opened at $207.13 on Tuesday. The company has a 50-day moving average price of $202.63 and a 200-day moving average price of $192.24. Biogen Inc. has a 52 week low of $127.71 and a 52 week high of $219.72. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of $30.60 billion, a P/E ratio of 36.66, a PEG ratio of 6.42 and a beta of 0.17.

Biogen (NASDAQ:BIIB – Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The company had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.46 billion. During the same quarter last year, the firm posted $5.47 earnings per share. The firm’s revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities research analysts anticipate that Biogen Inc. will post 12.5 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BIIB has been the topic of a number of research analyst reports. HSBC reaffirmed a “reduce” rating and set a $157.00 price target on shares of Biogen in a report on Monday, July 6th. Citigroup boosted their target price on Biogen from $200.00 to $215.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. Guggenheim upped their target price on shares of Biogen from $260.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Rothschild & Co Redburn raised their price target on shares of Biogen from $180.00 to $190.00 in a report on Thursday, April 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Biogen in a research note on Monday, June 22nd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $224.61.

View Our Latest Research Report on BIIB

About Biogen

(Free Report)

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

Featured Articles

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB – Free Report).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.